{
    "clinical_study": {
        "@rank": "50394", 
        "acronym": "STICS", 
        "arm_group": [
            {
                "arm_group_label": "Fluticasone 44 mcg", 
                "arm_group_type": "Active Comparator", 
                "description": "Fluticasone 44 mcg 2 puffs twice daily for 7 days intiated at the onset of \"yellow zone\" symptoms."
            }, 
            {
                "arm_group_label": "Fluticasone 220 mcg", 
                "arm_group_type": "Active Comparator", 
                "description": "Fluticasone 220 mcg 2 puffs twice daily for 7 days intiated at the onset of \"yellow zone\" symptoms."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to determine whether, in children receiving low-dose inhaled\n      corticosteroids (ICS), quintupling the dose of inhaled corticosteroids at the onset of\n      symptoms previously associated with upper respiratory illnesses and subsequent asthma\n      exacerbations reduces the rate of severe asthma exacerbations treated with oral\n      corticosteroids."
        }, 
        "brief_title": "Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "detailed_description": {
            "textblock": "The study design is a double-blind, parallel-group trial, including a total of 250\n      participants, ages 5-11 years, with a diagnosis of asthma and a history of at least 1 asthma\n      exacerbation treated with oral corticosteroids in the prior year. All participants will be\n      treated for 48 weeks with open-label fluticasone 44 mcg 2 puffs twice daily. During the\n      48-week treatment period, participants will receive randomized blinded therapy for 7 days\n      each time they enter the \"yellow zone\" (at the onset of symptoms previously associated with\n      upper respiratory illnesses and subsequent asthma exacerbations). Yellow zone therapy will\n      be fluticasone 44 or 220 mcg 2 puffs twice daily."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Physician-diagnosed asthma\n\n          -  At least 1 exacerbation treated with systemic (oral or injectable) corticosteroids in\n             the past 12 months\n\n          -  Able to perform reproducible spirometry\n\n          -  Current treatment with step 2 controller therapy [low-dose ICS, leukotriene receptor\n             antagonist (LTRA)] OR current treatment with step 3 controller therapy [low-dose ICS\n             + LABA, low-dose ICS + LTRA, or medium dose ICS] with a c-ACT score of >19, no more\n             than 2 prednisone treated exacerbations in the past 6 months, prebronchodilator FEV1\n             \u2265 80% predicted and willing to step down therapy OR controller na\u00efve and qualifying\n             for step 2 controller therapy [asthma symptoms or SABA use > 2 days per week or\n             night-time awakenings due to asthma > 2 nights per month]\n\n          -  Prebronchodilator FEV1 \u2265 60% predicted\n\n          -  Ability and willingness to provide informed assent\n\n          -  For females of childbearing potential: not pregnant, non-lactating, and agree to\n             practice an adequate birth control method.\n\n          -  History of clinical varicella or varicella vaccine\n\n        Exclusion Criteria:\n\n          -  Systemic (oral or injectable) corticosteroids within previous 2-week period\n\n          -  Current or recent (previous 2-weeks) use of medications known to significantly\n             interact with corticosteroid disposition, including but not limited to carbamazepine,\n             erythromycin, phenobarbital, phenytoin, rifampin, and ketoconazole\n\n          -  Presence of chronic or active lung disease other than asthma\n\n          -  Significant medical illness other than asthma, including thyroid disease, diabetes\n             mellitus, Cushing's disease, Addison's disease, hepatic disease, or concurrent\n             medical problems that could require oral corticosteroids during the study\n\n          -  A history of cataracts, glaucoma, or any other medical disorder associated with an\n             adverse effect to corticosteroids\n\n          -  History of a life-threatening asthma exacerbation requiring intubation, mechanical\n             ventilation, or resulting in a hypoxic seizure\n\n          -  More than 5 prednisone treated exacerbations in the past 12 months\n\n          -  More than 1 hospitalizations lasting >24 hours for asthma in the past 12 months\n\n          -  History of adverse reactions to ICS preparations or any of their ingredients\n\n          -  Receiving hyposensitization therapy other than an established maintenance regimen (On\n             maintenance regimen for \u2265 3 months)\n\n          -  History of premature birth before 35 weeks gestation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "11 Years", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02066129", 
            "org_study_id": "AsthmaNet 008"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fluticasone 44 mcg", 
                "description": "Fluticasone is an inhaled corticosteroid", 
                "intervention_name": "Fluticasone 44 mcg", 
                "intervention_type": "Drug", 
                "other_name": "Flovent\u00ae 44 mcg"
            }, 
            {
                "arm_group_label": "Fluticasone 220 mcg", 
                "description": "Fluticasone is an inhaled corticosteroid", 
                "intervention_name": "Fluticasone 220 mcg", 
                "intervention_type": "Drug", 
                "other_name": "Flovent\u00ae 220 mcg"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Fluticasone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Asthma", 
            "Fluticasone"
        ], 
        "lastchanged_date": "February 17, 2014", 
        "link": {
            "description": "AsthmaNet", 
            "url": "http://asthmanetresearch.org/"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85724"
                    }, 
                    "name": "University of Arizona College of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oakland", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94609"
                    }, 
                    "name": "Children's Hospital & Research Center Oakland"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143"
                    }, 
                    "name": "UCSF Benioff Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80206"
                    }, 
                    "name": "National Jewish Health"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32207"
                    }, 
                    "name": "Nemours Children's Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32827"
                    }, 
                    "name": "Nemours Children's Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "Emory University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60614"
                    }, 
                    "name": "Ann and Robert H. Lurie Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Rush University Medical Center/Stroger Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "University of Illinois at Chicago"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Children's Hospital Boston"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "St. Louis Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winston-Salem", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27157"
                    }, 
                    "name": "Wake Forest University Health Sciences"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "Rainbow Babies and Children's Hospital, Case Western Reserve University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15212"
                    }, 
                    "name": "Allegheny General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15224"
                    }, 
                    "name": "Children's Hospital of Pittsburgh of UPMC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53972"
                    }, 
                    "name": "University of Wisconsin"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations", 
        "overall_contact": {
            "email": "dtm5@psu.edu", 
            "last_name": "David Mauger, PhD"
        }, 
        "overall_official": {
            "affiliation": "University of Wisconsin, Madison", 
            "last_name": "William Busse, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Data and Safety Monitoring Board", 
                "United States: Federal Government", 
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome is the rate of severe asthma exacerbations treated with oral corticosteroids during the 48 week treatment period.", 
            "measure": "Asthma exacerbations", 
            "safety_issue": "No", 
            "time_frame": "end of 48 week treatment period"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02066129"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Milton S. Hershey Medical Center", 
            "investigator_full_name": "dave mauger", 
            "investigator_title": "Principal Investigator, AsthmaNet Data Coordinating Center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Milton S. Hershey Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Milton S. Hershey Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}